{
    "pmcid": "9158119",
    "qa_pairs": {
        "How does Nb-007 achieve high binding affinity to the S-RBD of SARS-CoV-2?": [
            "By forming extensive contacts with the S-RBD using its three CDRs",
            "By binding exclusively to the N-terminal domain of the spike protein",
            "By interacting with the S2 subunit of the spike protein",
            "By targeting the furin cleavage site of the spike protein"
        ],
        "What impact does the E484K mutation have on Nb-007's efficacy?": [
            "It significantly compromises binding to the Beta variant",
            "It enhances binding to the Delta variant",
            "It has no effect on binding to the original strain",
            "It improves neutralization of the Alpha variant"
        ],
        "What is the primary target of the nanobody Nb-007 developed in the study?": [
            "The spike receptor-binding domain (S-RBD) of SARS-CoV-2",
            "The nucleocapsid protein of SARS-CoV-2",
            "The membrane protein of SARS-CoV-2",
            "The envelope protein of SARS-CoV-2"
        ],
        "What potential therapeutic application is highlighted for Nb-007 in the study?": [
            "Combining with other nanobodies to form cocktails or bi-specific antibodies",
            "Using Nb-007 as a standalone treatment for all SARS-CoV-2 variants",
            "Administering Nb-007 in a monovalent form for increased specificity",
            "Developing Nb-007 as a vaccine adjuvant to boost immune response"
        ],
        "What strategy is suggested to enhance the efficacy of Nb-007 against SARS-CoV-2 variants?": [
            "Fusion with an Fc domain to increase avidity and serum half-life",
            "Targeting the nucleocapsid protein instead of the spike protein",
            "Reducing the size of Nb-007 to improve tissue penetration",
            "Using a single-domain format without any modifications"
        ]
    }
}